CA3071236A1 - Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient - Google Patents

Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient Download PDF

Info

Publication number
CA3071236A1
CA3071236A1 CA3071236A CA3071236A CA3071236A1 CA 3071236 A1 CA3071236 A1 CA 3071236A1 CA 3071236 A CA3071236 A CA 3071236A CA 3071236 A CA3071236 A CA 3071236A CA 3071236 A1 CA3071236 A1 CA 3071236A1
Authority
CA
Canada
Prior art keywords
amino acid
seq
acid sequence
hvr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3071236A
Other languages
English (en)
French (fr)
Inventor
Yuri TERANISHI
Kazuki Kato
Hikaru Koga
Tomoyuki Igawa
Kazuki Yamaguchi
Tetsuhiro Soeda
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CA3071236A1 publication Critical patent/CA3071236A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3071236A 2017-09-29 2018-09-27 Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient Pending CA3071236A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-189647 2017-09-29
JP2017189647 2017-09-29
PCT/JP2018/035832 WO2019065795A1 (ja) 2017-09-29 2018-09-27 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤

Publications (1)

Publication Number Publication Date
CA3071236A1 true CA3071236A1 (en) 2019-04-04

Family

ID=65902289

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3071236A Pending CA3071236A1 (en) 2017-09-29 2018-09-27 Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient

Country Status (24)

Country Link
US (3) US10759870B2 (https=)
EP (1) EP3690050A4 (https=)
JP (5) JP6496095B1 (https=)
KR (2) KR20200049764A (https=)
CN (2) CN111108202B (https=)
AR (1) AR113142A1 (https=)
AU (1) AU2018338859B2 (https=)
BR (1) BR112020005834A2 (https=)
CA (1) CA3071236A1 (https=)
CL (2) CL2020000767A1 (https=)
CO (1) CO2020003432A2 (https=)
CR (2) CR20210381A (https=)
EA (1) EA202090641A1 (https=)
IL (2) IL273592B2 (https=)
MA (1) MA50667A (https=)
MX (1) MX2020002710A (https=)
MY (1) MY204641A (https=)
PE (1) PE20210005A1 (https=)
PH (1) PH12020550162A1 (https=)
SG (2) SG11201810270SA (https=)
TW (3) TW202423960A (https=)
UA (1) UA128389C2 (https=)
WO (1) WO2019065795A1 (https=)
ZA (1) ZA202002151B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
RS67768B1 (sr) * 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
CN104011207B (zh) * 2011-10-31 2018-09-18 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
CN118440206A (zh) 2014-04-07 2024-08-06 中外制药株式会社 免疫活化抗原结合分子
EP3144388B1 (en) 2014-05-13 2020-07-01 Chugai Seiyaku Kabushiki Kaisha T cell-redirecting antigen-binding molecule for cells having immunosuppression function
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
KR102591955B1 (ko) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
EP3577140A1 (en) 2017-02-01 2019-12-11 Novo Nordisk A/S Procoagulant antibodies
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
AR113142A1 (es) 2017-09-29 2020-01-29 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
FR3082427B1 (fr) 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
PL3723858T3 (pl) 2018-12-21 2022-03-07 Kymab Limited Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
CR20220049A (es) 2019-07-10 2022-03-02 Chugai Pharmaceutical Co Ltd Moléculas de unión a claudina-6 y usos de las mismas
CN115052898B (zh) * 2020-01-30 2025-09-16 诺和诺德股份有限公司 双特异性因子viii模拟抗体
MX2022008339A (es) 2020-01-31 2022-08-04 Chugai Pharmaceutical Co Ltd Metodo para producir una composicion que contiene un polipeptido con coloracion suprimida.
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
CN115667515A (zh) * 2020-05-22 2023-01-31 中外制药株式会社 中和具有凝血因子viii(f.viii)功能替代活性的物质的抗体
AU2021278562A1 (en) 2020-05-29 2022-12-01 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
TW202333781A (zh) 2021-10-08 2023-09-01 日商中外製藥股份有限公司 抗ｈｌａ－ｄｑ２﹒５抗體製劑
WO2023147574A2 (en) * 2022-01-31 2023-08-03 The Children's Hospital Of Philadelphia Compositions and methods for treating factor ix deficiency
AR129879A1 (es) 2022-07-08 2024-10-09 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
MA71385A (fr) 2022-07-08 2025-04-30 Novo Nordisk A/S Composés isvd hautement puissants capables de remplacer fviii(a)
GB202316779D0 (en) * 2023-11-01 2023-12-13 Ucl Business Ltd Antigen binding protein
WO2025134341A1 (ja) * 2023-12-22 2025-06-26 中外製薬株式会社 抗体の製造方法
WO2025249551A1 (ja) * 2024-05-31 2025-12-04 中外製薬株式会社 二重特異性抗体のミスペア軽鎖交換体の定量方法

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
IL89491A0 (en) 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1991008770A1 (en) 1989-12-11 1991-06-27 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
TW212184B (https=) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH05184383A (ja) 1990-06-19 1993-07-27 Dainabotsuto Kk 二重特異性抗体
JPH05199894A (ja) 1990-08-20 1993-08-10 Takeda Chem Ind Ltd 二重特異性抗体および抗体含有薬剤
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JPH05304992A (ja) 1991-06-20 1993-11-19 Takeda Chem Ind Ltd ハイブリッド・モノクローナル抗体および抗体含有薬剤
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JPH06104071A (ja) 1991-08-30 1994-04-15 Jasco Corp 発熱体セラミックス溶接加工方法
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JPH05203652A (ja) 1992-01-28 1993-08-10 Fuji Photo Film Co Ltd 抗体酵素免疫分析法
JPH05213775A (ja) 1992-02-05 1993-08-24 Otsuka Pharmaceut Co Ltd Ｂｆａ抗体
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
AU7214294A (en) 1993-07-01 1995-01-24 Dade International Inc. Process for the preparation of factor x depleted plasma
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
AU702250B2 (en) 1994-07-11 1999-02-18 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
JPH10511085A (ja) 1994-12-02 1998-10-27 カイロン コーポレイション 二重特異性抗体を用いる免疫応答を促進する方法
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
JP3032287U (ja) 1996-06-10 1996-12-17 幸喜 高橋 人 形
JPH10165184A (ja) 1996-12-16 1998-06-23 Tosoh Corp 抗体、遺伝子及びキメラ抗体の製法
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
ES2210705T5 (es) * 1998-03-19 2011-02-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composición combinada que comprende una l-carnitina o una alcanoil-l-carnitina, un glucosaminoglucano y/o un constituyente del mismo.
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
JP4908721B2 (ja) 2000-07-17 2012-04-04 中外製薬株式会社 生理活性を有するリガンドのスクリーニング方法
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1327681A4 (en) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
EP1500665B1 (en) 2002-04-15 2011-06-15 Chugai Seiyaku Kabushiki Kaisha METHODS FOR CONSTRUCTING scDb LIBRARIES
DE60327199D1 (de) 2002-04-26 2009-05-28 Chugai Pharmaceutical Co Ltd Verfahren zum screening auf agonistische antikörper
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
AU2003303543A1 (en) 2002-12-26 2004-07-29 Chugai Seiyaku Kabushiki Kaisha Agonist antibody against heteroreceptor
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004065611A1 (ja) 2003-01-21 2004-08-05 Chugai Seiyaku Kabushiki Kaisha 抗体の軽鎖スクリーニング方法
KR101235507B1 (ko) 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
GB2400851B (en) 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
JP5490734B2 (ja) 2003-10-10 2014-05-14 中外製薬株式会社 機能蛋白質を代替する二種特異性抗体
WO2005035754A1 (ja) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2603264C (en) 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
KR101360671B1 (ko) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 ｓｃ（Ｆｖ）２를 함유하는 의약조성물
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
KR101856792B1 (ko) 2009-12-25 2018-05-11 추가이 세이야쿠 가부시키가이샤 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
US20140080153A1 (en) 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
US9683052B2 (en) * 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
CN104011207B (zh) 2011-10-31 2018-09-18 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
LT2794905T (lt) 2011-12-20 2020-07-10 Medimmune, Llc Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
ES2564281T3 (es) 2012-03-08 2016-03-21 F. Hoffmann-La Roche Ag Formulación de anticuerpos Abeta
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP2925785A4 (en) 2012-11-28 2016-11-16 Zymeworks Inc MANIPULATED IMMUNOGLOBULIN HEAVY CHAIN LIGHT CHAIN COUPLES AND USES THEREOF
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3142700B1 (en) 2014-05-16 2021-03-03 Medimmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
RU2729467C2 (ru) * 2014-05-28 2020-08-06 Займворкс Инк. Модифицированные антигенсвязывающие полипептидные конструкции и их применение
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
BR112016030740A2 (pt) 2014-07-01 2018-02-20 Pfizer Inc. diacorpos heterodiméricos biespecíficos e seus usos
AU2016245887B2 (en) 2015-04-10 2021-09-23 Adimab, Llc. Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
CA2978038A1 (en) 2015-04-17 2016-10-20 F. Hoffmann-La Roche Ag Combination therapy with coagulation factors and multispecific antibodies
JP2018123055A (ja) * 2015-04-24 2018-08-09 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
AU2017269115B2 (en) 2016-05-26 2024-06-20 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
EP3489262A4 (en) 2016-07-19 2020-07-08 Ibentrus, Inc. BISPECIFIC PROTEINS AND PROCESSES FOR THEIR PREPARATION
KR102591955B1 (ko) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
US20230192896A1 (en) * 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
US11149094B2 (en) 2017-06-05 2021-10-19 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
AR113142A1 (es) 2017-09-29 2020-01-29 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
CN115380210A (zh) 2020-04-02 2022-11-22 中外制药株式会社 含多特异性抗原结合分子的组合物中的杂质分子的分析方法

Also Published As

Publication number Publication date
SG10202007194PA (en) 2020-08-28
TW202423960A (zh) 2024-06-16
JP2024156791A (ja) 2024-11-06
US12522668B2 (en) 2026-01-13
JP2023110093A (ja) 2023-08-08
PH12020550162A1 (en) 2021-02-22
KR20190039020A (ko) 2019-04-10
CL2022000250A1 (es) 2022-11-25
IL273592A (en) 2020-05-31
CN111108202B (zh) 2024-10-22
ZA202002151B (en) 2025-11-26
CR20200158A (es) 2020-06-14
MX2020002710A (es) 2020-07-20
IL273592B1 (en) 2025-07-01
JP7652836B2 (ja) 2025-03-27
CN111108202A (zh) 2020-05-05
EP3690050A4 (en) 2021-06-16
CN118994408A (zh) 2024-11-22
AU2018338859A1 (en) 2020-02-06
AR113142A1 (es) 2020-01-29
JP6496095B1 (ja) 2019-04-03
TW201920253A (zh) 2019-06-01
IL273592B2 (en) 2025-11-01
PE20210005A1 (es) 2021-01-05
TW201936634A (zh) 2019-09-16
TWI667254B (zh) 2019-08-01
EP3690050A1 (en) 2020-08-05
EA202090641A1 (ru) 2020-08-07
US20260103540A1 (en) 2026-04-16
JPWO2019065795A1 (ja) 2019-11-14
SG11201810270SA (en) 2019-04-29
AU2018338859B2 (en) 2025-06-26
KR20200049764A (ko) 2020-05-08
JP2019129829A (ja) 2019-08-08
UA128389C2 (uk) 2024-07-03
KR102078957B1 (ko) 2020-02-20
US20200354473A1 (en) 2020-11-12
CO2020003432A2 (es) 2020-04-13
MA50667A (fr) 2020-08-05
BR112020005834A2 (pt) 2020-09-24
CR20210381A (es) 2021-09-09
US20200223940A1 (en) 2020-07-16
RU2020112677A (ru) 2021-10-29
CL2020000767A1 (es) 2020-11-20
JP2025061487A (ja) 2025-04-10
MY204641A (en) 2024-09-06
US10759870B2 (en) 2020-09-01
WO2019065795A1 (ja) 2019-04-04
IL284913A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
US20260103540A1 (en) Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient
JP7472056B2 (ja) ＦｃＲＨ５に対するヒト化親和性成熟抗体及び使用方法
US12240910B2 (en) Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use
KR20170086549A (ko) 항-CD79b 항체 및 이용 방법
RU2854450C2 (ru) Мультиспецифическая антигенсвязывающая молекула, обладающая замещающей функциональной активностью кофактора коагулирующего фактора крови viii, и фармацевтическая композиция, содержащая указанную молекулу в качестве активного ингредиента
RU2812909C2 (ru) Мультиспецифическая антигенсвязывающая молекула, обладающая замещающей функциональной активностью кофактора коагулирующего фактора крови viii, и фармацевтическая композиция, содержащая указанную молекулу в качестве активного ингредиента
HK40112235A (zh) 具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂
JP7220335B1 (ja) 抗ｈｌａ－ｄｑ２．５抗体の製剤
HK40027191B (zh) 具有凝血因子viii( fviii )辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂
EP4731255A1 (en) Treatment of multiple myeloma
HK40027191A (en) Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240916

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240916

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240916

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250109

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250625

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250625

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250916

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250916